Merck Expands Animal-Health Business with Acquisition of Elanco’s Aqua Business

In a move that solidifies its position in the animal-health industry, pharmaceutical giant Merck has struck a deal to purchase Elanco Animal Health’s aqua business. This strategic acquisition will not only expand Merck’s portfolio of animal health products, but also strengthen its presence in the aquaculture market.

The deal, which is expected to close in the second half of 2021, will see Merck acquire Elanco’s aqua business for $450 million in cash. This includes Elanco’s aquaculture research and development pipeline, as well as its existing portfolio of products for fish and shrimp health.

This acquisition is a significant step for Merck, as it further diversifies its animal-health business beyond its current focus on livestock and companion animals. With the global aquaculture market projected to reach $274.8 billion by 2025, according to a report by Grand View Research, this move positions Merck to tap into the growing demand for aquaculture products.

In addition to expanding its product offerings,  

Share This Article
Leave a comment